Melbourne Clinical Trials
The Longevity Study
The study drug is a potential treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
3 overnight stays + 1 set of 2- nights
1 phone call + 12 visits
ADPKD is the most common genetic cause of kidney disease affecting up to 12 million people globally and accounts for up to 10% of dialysis (is a way to clean your blood if your kidneys are not working properly) patients.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!
Eligibility
Biological sex Male or Female of non-childbearing potential
Age 18 – 65 years old
BMI 18–32 kg/m2
Weight Male: ≥50 kg, Female: ≥45 kg
Medical History No significant medical history
Medication Not taking any prescription medication